SCHEMBL27162174

SCHEMBL27162174

N#Cc1ccc(CN2CCC3(CCCN(S(=O)(=O)c4ccc(N5CCOCC5)nc4)C3)CC2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ LMNA P02545 2/20 0.49
▸ GAA P10253 4/20 0.46
▸ TSHR P16473 3/20 0.46
▸ CYP3A4 P08684 5/20 0.44
▸ CYP2D6 P10635 4/20 0.44
▸ USP2 O75604 4/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CACNA1H O95180 2/20 0.44
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ KCNJ1 P48048 1/20 0.39
▸ SCN9A Q15858 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PARG Q86W56 1/20 0.37
▸ TRPV4 Q9HBA0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050943 1.00 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL30049557 0.83 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL27162302 0.83 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL27161993 0.83 CYP3A4 (0.58) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL30050081 0.83 CYP3A4 (0.58) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL30050718 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL27162872 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL30049800 0.81 CYP3A4 (0.43) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL27162660 0.81 CYP3A4 (0.43) SMN1; SMN2ALDH1A1LMNAGAATSHR
SCHEMBL30050906 0.80 CYP3A4 (0.47) SMN1; SMN2ALDH1A1LMNAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 SMN1; SMN2 3118/4885ALDH1A1 1011/4885LMNA 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback